AVCT vs. PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, BVXP, 4BB, and TILS
Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.
Avacta Group vs. Its Competitors
Avacta Group (LON:AVCT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Avacta Group has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.
Avacta Group has a net margin of -114.45% compared to PureTech Health's net margin of -17,620.94%. PureTech Health's return on equity of -21.15% beat Avacta Group's return on equity.
In the previous week, Avacta Group and Avacta Group both had 1 articles in the media. PureTech Health's average media sentiment score of 1.47 beat Avacta Group's score of 0.00 indicating that PureTech Health is being referred to more favorably in the news media.
10.2% of Avacta Group shares are held by institutional investors. Comparatively, 79.9% of PureTech Health shares are held by institutional investors. 32.9% of Avacta Group shares are held by company insiders. Comparatively, 15.9% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
PureTech Health has a consensus price target of GBX 455, suggesting a potential upside of 251.62%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.
Summary
PureTech Health beats Avacta Group on 8 of the 15 factors compared between the two stocks.
Get Avacta Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avacta Group Competitors List
Related Companies and Tools
This page (LON:AVCT) was last updated on 7/3/2025 by MarketBeat.com Staff
